Iman Wanis, Cushla Coffey, Shaffiq Essajee, and Philippa Easterbrook World Health Organization, HIV Department (ATC) Geneva, Switzerland July 2011 COSTING.

Slides:

Advertisements

Similar presentations

Overview of the medicine prices and availability survey methodology Presentation template for adaptation and use in medicine prices and availability survey.

Advertisements

MDG Target 8.E gap analysis Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical Policies, World Health Organization 27 August 2008.

Strengthening the Pharmaceutical Sector: Mechanisms to Monitor Performance Douglas L. Keene June 15, 2010.

Providing Quality Medicines for People Living with and Affected by HIV and AIDS Supply Chain Management System Project The Partnership for Supply Chain.

A Call to Action Children – The missing face of AIDS.

Group III: Demand Forecasting

Harmonization of donor reporting requirements for antiretrovirals and related drugs Presented at the WHO meeting, Geneva ( October 2005) Oteba Olowo.

National PSM Coordination Mechanism Dr Vincent Habiyambere WHO/HIV Department AIDS Medicines & Diagnostics Service (AMDS) Bangkok, July 2005.

AMDS Contribution to the Technical Briefing Seminar October 2007.

THE INTERNATIONAL DRUG PURCHASE FACILITY-UNITAID Michel D. Kazatchkine, Ministère des Affaires Etrangères, France.

Excellent healthcare – locally delivered What’s new in the diagnosis, prevention and management of HIV-related cryptococcal disease Nelesh Govender (on.

WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies

The South African Cryptococcal Screening Program: Program update XIX international AIDS Conference Washington United States 24 th July 2012 Dr. Samuel.

Introduction to Treat the Pain. The problem of unrelieved pain Globally, 7.3 million people die of cancer or HIV each year in moderate or severe pain.

Scaling up Prevention of Mother to Child Transmission of HIV (PMTCT): What Will it Take to Eliminate MTCT? Jessica Rodrigues Presentation for UNICEF Written.

Pharmacy & National Procurement Christine Gilmour Chief Pharmacist NHS Lanarkshire.

Methods for Estimating Global Resource Needs for HIV/AIDS John Stover, Lori Bollinger International AIDS Economic Network Meeting, Washington,

Dr. Yogan Pillay Deputy Director General National Department of Health, South Africa Monday 1 July 2013 OPERATIONAL AND PROGRAMMATIC CONSIDERATIONS IN.

Application of an International Reference Price List to National Medicines Procurement Tenders Bada Pharasi, Gavin Steel, Jean-Pierre Sallet, SPS, Management.

Affordability of HIV/AIDS treatment in developing countries: modeling ARV drug price determinants for a better understanding of the market functioning.

Screen-and-Treat A new strategy to prevent cryptococcal deaths.

Iman Wanis and Philippa Easterbrook World Health Organization, HIV Department (ATC) Geneva, Switzerland July 2011 What is the reality in the field? Survey.

Is the pricing of antiretrovirals equitable? Analysis of antiretroviral drug prices in 20 low and middle income countries Andrew Hill, Pharmacology and.

HIV Therapy for the Developing World: A Global Health Challenge Harold W. Jaffe, MD Department of Public Health University of Oxford Oxford, UK.

PROCUREMENT SUPPORT SERVICE WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies, November 1 st -5 th 2010 Mariatou Tala Jallow, Manager,

Jacqui Patterson Interchurch Medical Assistance (IMA) CCIH, May 2003 The Diflucan Partnership Program: IMA & Pfizerwww.diflucanpartnership.org.

Wilbert Bannenberg SARPAM

Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.

COST-BENEFIT OF INTEGRATING CRYPTOCOCCAL ANTIGEN SCREENING AND PREEMPTIVE TREATMENT INTO ROUTINE HIV CARE Radha Rajasingham, David Meya, Melissa Rolfes,

Botswana Experience on Public- Private Partnerships Joconiah Chirenda, MD, MPH, MBA Global Business Coalition on.

2013 WHO Consolidated ARV Guidelines Summary of Major Recommendations and Estimated Impact GSG Briefing July 19, 2013 Gottfried Hirnschall, Director HIV.

RHSC Meeting Kampala, May 2010 Quality for Medicines The Global Fund approach Sophie Logez Manager, QA and Data Quality Pharmaceutical Management.

Zimbabwe MOHCW Male Circumcision Programme Supply Chain Management Dr. O. Mugurungi, Director AIDS&TB Programme Ministry of Health and Child Welfare June.

Medicine Prices, Availability, Affordability and Price Components in Kazakhstan, Kyrgystan, Tajikistan & Uzbekistan Margaret Ewen Health Action International.

Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.

MALAWI GOVERNMENT MINISTRY OF HEALTH PROGRESS ON GOOD GOVERNANCE IN THE PHARMACEUTICAL SECTOR IN MALAWI By Dr Charles Mwansambo Secretary for Health 20.

Meg O’Brien, Ph.D. Director, Global Access to Pain Relief Initiative Procurement & Manufacture of IR Oral Morphine: Uganda experience 1.

Treating MDR-TB A Challenge Throughout ECA Public Health Practice II.

WHO-HIV Department Strategic Information Unit AIDS Medicines and Diagnostics Service Contribution to Access to medicines Technical Briefing Seminar, November.

2004: 39.4 (35.9 – 44.3) million Western & Central Europe [ – ] North Africa & Middle East [ – 1.5 million] Sub-Saharan.

TB Public Private Partnerships Opportunity or Risk? Cheri Vincent Senior Public Health Advisor USAID June 3, 2008.

Adhoc Committee on Health 22 June DISPENSING LICENCE  Have 4 providers for the course 1. Health Science Academy 2. Intec College 3. Medunsa 4.

From 3by5 to Universal Access to HIV/AIDS Treatment: AMDS Technical Briefing Seminar for Consultants on Procurement and Supply Management for HIV, TB and.

Affordability of HIV/AIDS treatment in developing countries: an analysis of ARV drug price determinants Luis Sagaon Teyssier; Yves Arrighi; Boniface Dongmo.

CLICK TO ADD TITLE [DATE][SPEAKERS NAMES] The 5th Global Health Supply Chain Summit November , 2013 Addis Ababa, Ethiopia Country-level Coordinated.

Access to Paediatric ARV Formulations Provisions for Children.

Zokufa HZ, Pillay T Pharmaceutical Policy and Planning National Department of Health- South Africa.

Out-of-pocket and Out-of-reach Margaret Ewen, Coordinator, Global Projects (Pricing) Health Action International Amsterdam.

MONITORING MEDICINE AVAILABILITY AND PRICES IN UGANDA By Denis Kibira HEPS Uganda.

Selection of essential medicines Richard Laing and Deidre Dimancesco TBS 2011 Department of Essential Medicines & Pharmaceutical Policies TBS 2008.

WHO Medicines Strategy Progress: Priorities: Dr Guitelle Baghdadi Essential Drugs and Medicines Policy World Health Organization November.

1 Scaling-up ARV Therapy in Vietnam HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Expenditure tracking in health care National Health Accounts Tomas Roubal WHO, South Africa.

Supporting access to quality paediatric ARVs Atieno Ojoo Technical Specialist, Pharmaceuticals UNICEF Supply Division IAS satelite session on Essential.

Optimizing the Cost and Quality of HIV / AIDS Care and Treatment Anil Soni, Clinton HIV / AIDS Initiative 19 th Board Meeting, Geneva 6 May 2009.

The price trends of HIV/AIDS medicines: Finding and using data Dr. Perriëns Joseph Coordinator SSH Unit, WHO.

HIV Post Exposure Prophylaxis

WHO Medicines Work in Countries: The Kenya Example

IDA Solutions Clarisse Morris, MA January 2006

Expanding ARV treatment in developing countries: Issues and Prospects

World Health Organization

B. Dongmo Nguimfack AMDS TCO Unit/HIV, WHO

AMDS Products, events and issues.

Enablers for nationwide expansion of collaborative TB/HIV activities

Essential Drugs and Medicines Policy (EDM) World Health Organization

July 21, 2016 Potential Domestic Source Financing for Scaled Up Antiretroviral Therapy in 97 Countries, 2016–2020 Arin Dutta, Catherine Barker, and Ashley.

Commonalities across treatments and diseases: A brief overview

Iman Wanis and Philippa Easterbrook World Health Organization, HIV Department (ATC) Geneva, Switzerland July 2011 What is the reality in the field? Survey.

Update on global progress in ART

Prioritizing Advanced HIV Disease and Overcoming Barriers to Access Carolyn Amole Senior Director, HIV Access Program, CHAI Satellite: Saving Lives Today:

Presentation transcript:

Iman Wanis, Cushla Coffey, Shaffiq Essajee, and Philippa Easterbrook World Health Organization, HIV Department (ATC) Geneva, Switzerland July 2011 COSTING AND AVAILABILITY OF DRUG THERAPY AND DIAGNOSTIC ASSAYS FOR CRYPTOCOCCAL INFECTION

CRYPTOCOCCAL DRUGS AND DIAGNOSTICS

Funding and Supply/Distributors for Drugs UNITAID/CHAI The Global Fund PEPFAR National Government NGOs e.g. MSF Self-pay

Challenges in the use of supplied medicines Orders were low Stock went unused Countries had difficulty predicting need Countries were not able to track cases or monitor use Lack of consistent country practice and the need for clear guidance

UNITAID/CHAI Progress of the projects Performance of suppliers Achievement of key objectives * Source: A meeting with UNITAID/CHAI Pediatrics ARVs Project Coordinator

Programmatic Experience in UNITAID/CHAI Pediatric Amphotericin Donation Programme Underutilised, orders were low Clinicians not well informed about programme (reports of unused or expiring stock in pharmacy) Not clear whether drugs are used for children or adults No standardisation of process e.g. Tracking and monitoring of use Liaison with clinics Forecasting/product quantifications Need for consistent country practice and guidance

Data Sources for Drug Costs 1. International Drug Price Indicator Guide (IDPI) -Published by Management Sciences for Health (MSH) since Annually updated -Prices from pharmaceutical suppliers, international development organizations, and government agencies 2. Global Price Reporting Mechanism (GPRM) -Web-based database launched by the AMDS in April Reports of price quotes from pharmaceutical companies, and other sources. -Price monitoring tool -Prices of drugs purchased and supplied by various procuring agencies for different countries: CHAI, Mission Pharma, MSH, PFSCMS, UNDP, UNFPA, UNICEF, UNITAID 4. Telephone Country Survey: 8 HIV clinicians, 1 laboratory director, 1 clinical microbiologist, 1 pharmacist, NAP director and 1 Information Management advisor.

Amphotericin B (ampho) + Fluconazole (fluc) Costs in Sub Saharan Africa (GPRM) Uganda (2009) $2.6/50mg ampho $0.7/200mg fluc Angola (2008) $12.31/50mg ampho $0.174/200mg fluc Burundi (2009) $2.6/50mg ampho $0.07/200mg fluc Malawi (2009) $2.48/50mg ampho $0.07/200mg fluc

Comparison of Costs of Amphotericin B and Fluconazole in IDPI (2010) & GPRM ( ) Databases & Field Data Amphotericin B (50mg) 1vial/day x 14 days Fluconazole (200mg) 800mg/day x 14 days Median Price (unit price) Lowest Price (unit price) Highest Price (unit price) Median Price (unit price) Lowest Price (unit price) Highest Price (unit price) IDPI Supplier 2010 $88.90 ($6.350) $49.14 ($3.510) $ ($7.863) $1.22 ($0.087) $1.08 ($0.077) $1.36 ($0.097) IDPI Buyer 2010 $73.79 ($5.271) $59.22 ($4.230) $ ($12.200) $9.07 ($0.162) $2.24 ($0.040) $18.87 ($0.337) GPRM $36.40 ($2.60) $29.82 ($2.13) $ ($12.42) $3.92 ($0.07) $1.12 ($0.02) $18.48 ($0.33) Field Data South Africa $14 ($1 – BMS) $1400 ($100–Generic) $69.86 ($4.99) (Private/Public sectors) South Africa Ambisone $ (Generic- Private) >$ (Public) Uganda $81.9- $ ($ $7.81) $140-$168 ($10-$12) Botswana $ 50/month

Flucytosine Cost estimates from World Wide Web resources Oral capsules IV infusion Brand nameAncobon 500mgAncobonAncotil 2.5g/250ml Solution for Infusion CompanyValeant Pharmaceuticals Ltd. California, USA ICN PharmaceuticalsMeda Pharmaceuticals Ltd United Kingdom Strength500mg250 mg 100/caps 500 mg 100/caps Flucytosine Ph. Eur. 2.5g in 250 ml.) Unit price$49.05$22.64 $43.81 $48.86 (10mg/ml) Treatment course (100mg/50kg/day)x14 $6,867 $3, $6, Other sourcesJohn Bell Croydon Pharmacy in London: $ 24.16/day Treatment course (100mg/50kg/day)x14 $210 $3.22/tablet ($ 32.22/day) Treatment course (100mg/50kg/day)x14 $280

Diagnostics Cost Estimates from the field India InkCRAG LACRAG LFACulture South Africa$5.79$2 Uganda$5.85 or $1.92 $ Malwai$ Immy Diagnostic Tests manufacturer <$1$2 <$1 Manufacturer Immy Meridian Biosciences Remel BioRad Alere (Inverness) Supplier SCMS National governments PEPFAR LA= CRAG Latex Agglutination LFA= CRAG Lateral Flow Assay SCMS= Supply Chain Management System

Cost estimates from Literature Meya et al. Uganda 2010 Micol et al. Cambodia (MSF) (3 month costs) Parkes-Ratanshi et al. Uganda 2011 Cotrimoxazole prophylaxis$0.89 Fluconazole prophylaxis$3.47 cART$91.50 CM/pulmonary cryptococcosis treatment and care $245 per course (amphotericin B) $ Other opportunistic infection treatment and care $ CrAg screening test$16.75$6.63$16 Fluconazole prophylaxis unit price is $0.15(200mg capsule $0.45 per week, 35 weeks)$15.75 Administration and dispensing costs (per patient)$2 Training costs (per patient)$2 Other costs (per patient)$2 Total costs of FCP:$21.75

Data Limitations GPRM  Data ranges from 2004 – 2010, so comparisons between countries difficult  Data from only a few manufacturers. Comparisons between IDPI, GPRM unreliable because:  Multiple sources of data from manufacturers (GPRM), suppliers and buyers  Data from different years.